PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33922418-4 2021 EchA treatment reduces the number of activated myofibroblasts expressing alpha-SMA, vimentin, and phosphorylated Smad3 in bleomycin-induced scleroderma. Bleomycin 122-131 SMAD family member 3 Mus musculus 113-118 31775746-9 2019 EMT was measured and transforming growth factor-beta (TGF-beta)/Smad3 signaling was evaluated in the lungs of BLM-treated mice. Bleomycin 110-113 SMAD family member 3 Mus musculus 64-69 33101446-0 2020 Feibi Recipe Reduced Pulmonary Fibrosis Induced by Bleomycin in Mice by Regulating BRP39/IL-17 and TGFbeta1/Smad3 Signal Pathways. Bleomycin 51-60 SMAD family member 3 Mus musculus 108-113 31940650-12 2020 CONCLUSION: GAA has protective effect on BLM-induced lung injury, and TGF-beta/Smad-3/NF-kappaB signaling pathway may play an important role in the pathogenesis of BLM-induced lung injury. Bleomycin 164-167 SMAD family member 3 Mus musculus 79-85 31775746-14 2019 Pulmonary TGF-beta/Smad3 signaling was activated in BLM-induced lung fibrosis. Bleomycin 52-55 SMAD family member 3 Mus musculus 19-24 31775746-16 2019 Moreover, feeding VDD diet aggravated BLM-induced TGF-beta/Smad3 activation and subsequent EMT in the lungs. Bleomycin 38-41 SMAD family member 3 Mus musculus 59-64 28694203-0 2017 Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways. Bleomycin 51-60 SMAD family member 3 Mus musculus 118-123 29926545-11 2019 In a bleomycin-induced lung injury mouse model, RA decreased the expression of TGF-beta1 and Smad3 at 1 and 3 weeks. Bleomycin 5-14 SMAD family member 3 Mus musculus 93-98 30470612-11 2018 INTERPRETATION: The application of the combined siRNAs of SPARC, CCR2, and SMAD3 genes ameliorated inflammation and fibrosis in bleomycin-induced mice. Bleomycin 128-137 SMAD family member 3 Mus musculus 75-80 31108104-0 2019 Progranulin Promotes Bleomycin-Induced Skin Sclerosis by Enhancing Transforming Growth Factor-beta/Smad3 Signaling through Up-Regulation of Transforming Growth Factor-beta Type I Receptor. Bleomycin 21-30 SMAD family member 3 Mus musculus 99-104 29913150-0 2018 SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice. Bleomycin 48-57 SMAD family member 3 Mus musculus 30-35 22398790-4 2012 In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed. Bleomycin 10-19 SMAD family member 3 Mus musculus 87-94 28533545-0 2017 Treatment effects of the traditional Chinese medicine Shenks in bleomycin-induced lung fibrosis through regulation of TGF-beta/Smad3 signaling and oxidative stress. Bleomycin 64-73 SMAD family member 3 Mus musculus 127-132 27777101-4 2017 Glycyrrhizin significantly ameliorated dermal fibrosis in bleomycin-treated mice, which was partly attributable to blockade of transforming growth factor-beta signaling in dermal fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-beta receptor, and transcription factors Smad3 and Ets1. Bleomycin 58-67 SMAD family member 3 Mus musculus 317-322 25356121-0 2014 Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-beta, Smad3 and JAK-STAT pathway. Bleomycin 25-34 SMAD family member 3 Mus musculus 83-88 23161884-2 2013 We showed previously that null mutation of Smad3, a critical node in the TGF-beta pathway, protects mice against fibrosis induced by bleomycin. Bleomycin 133-142 SMAD family member 3 Mus musculus 43-48 22395530-5 2012 This was evidenced by the findings that mice or pulmonary fibroblasts null for Smad3 were protected against bleomycin or TGF-beta1-induced loss of miR-29 along with fibrosis in vivo and in vitro. Bleomycin 108-117 SMAD family member 3 Mus musculus 79-84 28263294-3 2017 A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation. Bleomycin 32-41 SMAD family member 3 Mus musculus 213-218 28263294-3 2017 A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-beta bioavailability as well as SMAD3 phosphorylation. Bleomycin 43-46 SMAD family member 3 Mus musculus 213-218 22687409-4 2012 In Western blotting of the right lung tissues and immunohistochemical assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-beta signals were blocked meanwhile. Bleomycin 177-186 SMAD family member 3 Mus musculus 156-161 22398790-4 2012 In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed. Bleomycin 10-19 SMAD family member 3 Mus musculus 98-105 22398790-4 2012 In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed. Bleomycin 163-172 SMAD family member 3 Mus musculus 87-94 22398790-4 2012 In murine bleomycin-induced pulmonary fibrosis, nuclear localization of phosphorylated Smad2/3 (p-Smad2/3) was observed in pulmonary fibrotic lesions 7 days after bleomycin injection, whereas alpha-smooth muscle actin (ASMA)-positive myofibroblasts appeared in the lesions at 14 days, when the cytoplasmic localization of p-Smad2/3 was observed. Bleomycin 163-172 SMAD family member 3 Mus musculus 98-105 17065376-7 2006 Surprisingly, although Smad3 null mice, deficient in TGF-beta signal transmission, are resistant to bleomycin- and TGF-beta-mediated fibrosis, they develop spontaneous age-related airspace enlargement, consistent with emphysema, with a lack of ability to repair tissue damage appropriately. Bleomycin 100-109 SMAD family member 3 Mus musculus 23-28 18976720-7 2009 Early administration of SU5416 inhibited pulmonary collagen deposition, histopathologic fibroplasias and the activation of TGF-beta1/Smad3 signaling pathway in bleomycin-stimulated lung. Bleomycin 160-169 SMAD family member 3 Mus musculus 133-138 17303001-6 2007 We induced Smad3 knockout mice lung fibrosis by bleomycin. Bleomycin 48-57 SMAD family member 3 Mus musculus 11-16 17303001-11 2007 Compared to wild-type mice, Smad3 knockout mice showed attenuated lung fibrosis after bleomycin treatment, manifested by lower collagen production and myofibroblast differentiation. Bleomycin 86-95 SMAD family member 3 Mus musculus 28-33 15154911-6 2004 Smad3 null mice are resistant to radiation-induced cutaneous fibrosis, bleomycin-induced pulmonary fibrosis, carbon tetrachloride-induced hepatic fibrosis as well as glomerular fibrosis induced by induction of type 1 diabetes with streptozotocin. Bleomycin 71-80 SMAD family member 3 Mus musculus 0-5 16438734-13 2006 The expression of Smad3 and Smad4 mRNA was clearly attenuated by bleomycin, but was recovered by EM703. Bleomycin 65-74 SMAD family member 3 Mus musculus 18-23 15215176-7 2004 Electron microscopy revealed an absence of small diameter collagen fibrils in the dermis from bleomycin-treated Smad3(-/-) mice. Bleomycin 94-103 SMAD family member 3 Mus musculus 112-117 15215176-9 2004 Together, these results indicate that ablation of Smad3 is associated with markedly altered fibroblast regulation in vivo and in vitro, and confers partial protection from bleomycin-induced scleroderma in mice. Bleomycin 172-181 SMAD family member 3 Mus musculus 50-55 12839562-6 2003 Importantly, in bleomycin-injected skin, fibroblasts showed predominantly nuclear localization of Smad3 and intense staining for phospho-Smad2/3. Bleomycin 16-25 SMAD family member 3 Mus musculus 98-103 34142927-0 2021 Glycyrrhizic acid, as an inhibitor of HMGB1, alleviates bleomycin-induced pulmonary toxicity in mice through the MAPK and Smad3 pathways. Bleomycin 56-65 SMAD family member 3 Mus musculus 122-127 11839555-4 2002 Mice deficient in Smad3 demonstrated suppressed type I procollagen mRNA expression and reduced hydroxyproline content in the lungs compared with wild-type mice treated with bleomycin. Bleomycin 173-182 SMAD family member 3 Mus musculus 18-23 11839555-5 2002 Furthermore, loss of Smad3 greatly attenuated morphological fibrotic responses to bleomycin in the mouse lungs, suggesting that Smad3 is implicated in the pathogenesis of pulmonary fibrosis. Bleomycin 82-91 SMAD family member 3 Mus musculus 21-26 11839555-5 2002 Furthermore, loss of Smad3 greatly attenuated morphological fibrotic responses to bleomycin in the mouse lungs, suggesting that Smad3 is implicated in the pathogenesis of pulmonary fibrosis. Bleomycin 82-91 SMAD family member 3 Mus musculus 128-133 11839555-6 2002 These results show that Smad3 contributes to bleomycin-induced lung injury and that Smad3 may serve as a novel target for potential therapeutic treatment of lung fibrosis. Bleomycin 45-54 SMAD family member 3 Mus musculus 24-29 34666752-5 2021 Bleomycin-challenged mice treated with dual alphavbeta6/alphavbeta1 integrin inhibitor, PLN-74809, were assessed for changes in pulmonary collagen deposition and Smad3 phosphorylation. Bleomycin 0-9 SMAD family member 3 Mus musculus 162-167 11839555-0 2002 Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Bleomycin 28-37 SMAD family member 3 Mus musculus 0-5 34142927-8 2021 However, early (from day 0 to 14 after bleomycin instillation) or late (from day 14 to 28) intervention with HMGB1 neutralizing antibody or glycyrrhizic acid alleviated inflammation and fibrosis through down-regulating the inflammatory signaling mitogen-activated protein kinase (MAPK) and fibrotic signaling Smad3 pathway. Bleomycin 39-48 SMAD family member 3 Mus musculus 309-314 35126110-0 2021 Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-beta/Smad3 Pathway. Bleomycin 36-45 SMAD family member 3 Mus musculus 96-101 35187969-0 2022 Protective effects of alpha-lipoic acid on bleomycin-induced skin fibrosis through the repression of NADPH Oxidase 4 and TGF-beta1/Smad3 signaling pathways. Bleomycin 43-52 SMAD family member 3 Mus musculus 131-136